Τίτλος:
Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The expression patterns and prognostic significance of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) protein in the neoplastic Hodgkin and Reed Sternberg (HRS) cells of Hodgkin lymphoma (HL) were investigated in a cohort of 154 patients with HL treated with standard regimens. SAMHD1 expression was assessed by immunohistochemistry using diagnostic lymph node biopsies obtained prior to treatment. Using an arbitrary 20% cut-off, SAMHD1 was positive in HRS cells of 48/154 (31·2%) patients. SAMHD1 expression was not associated with clinicopathologic parameters, such as age, gender, stage or histologic subtype. In 125 patients with a median follow-up of 90 months (7–401 months), SAMHD1 expression in HRS cells significantly correlated with inferior freedom from progression (FFP) (P = 0·025), disease-specific survival (DSS) (P = 0·013) and overall survival (OS) (P = 0·01). Importantly, in multivariate models together with disease stage, histology subtype and type of treatment as covariates, SAMHD1 expression retained an independent significant association with unfavourable FFP (P = 0·005) as well as DSS (P = 0·022) and OS (P = 0·018). These findings uncover the significance of a novel, adverse prognostic factor in HL that may have therapeutic implications since SAMHD1 inhibitors are now available for clinical use. © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Συγγραφείς:
Xagoraris, I.
Vassilakopoulos, T.P.
Drakos, E.
Angelopoulou, M.K.
Panitsas, F.
Herold, N.
Medeiros, L.J.
Giakoumis, X.
Pangalis, G.A.
Rassidakis, G.Z.
Περιοδικό:
British Journal of Haematology
Εκδότης:
Wiley-Blackwell Publishing Ltd
Λέξεις-κλειδιά:
bleomycin; chlormethine; dacarbazine; doxorubicin; membrane protein; mitoxantrone; prednisone; procarbazine; sterile alpha motif and HD domain containing protein 1; unclassified drug; vinblastine; vincristine; antineoplastic agent; bleomycin; dacarbazine; deoxynucleoside triphosphate triphosphohydrolase SAMHD1; doxorubicin; SAMHD1 protein, human; vinblastine, adolescent; adult; age; aged; Article; cancer prognosis; cancer staging; cancer therapy; classical Hodgkin lymphoma; clinical feature; clinical outcome; cohort analysis; controlled study; disease specific survival; female; follow up; freedom from progression; gender; histology; human; human cell; immunohistochemistry; lymph node biopsy; major clinical study; male; overall survival; patient care; priority journal; protein expression; protein function; Reed Sternberg cell; survival; treatment duration; biosynthesis; clinical trial; disease free survival; drug effect; enzymology; gene expression regulation; Hodgkin disease; lymph node; middle aged; mortality; survival rate; tumor cell line; very elderly, Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Line, Tumor; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; SAM Domain and HD Domain-Containing Protein 1; Survival Rate; Vinblastine
